Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290879 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1POLBMCL1CYP1A2 | |
| SCHEMBL3841134 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1POLBMCL1CYP1A2 | |
| Cis-3-Hexenol SCHEMBL3676741 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TDP1 | |
| Cis-3-Hexenol SCHEMBL3676743 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL8145148 | 0.83 | ALDH1A1 (0.40) | ALDH1A1TDP1POLBMCL1 | |
| SCHEMBL8604295 | 0.83 | ALDH1A1 (0.40) | ALDH1A1TDP1POLBMCL1 | |
| (Z)-Hex-3-En-1-Yl Acetate SCHEMBL4013342 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| (Z)-Hex-3-En-1-Yl Acetate SCHEMBL4013348 | 0.80 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| SCHEMBL8140336 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TDP1POLBMCL1 | |
| SCHEMBL8607166 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TDP1POLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4695016-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4581114-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Novozymes A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| WO-2024213507-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | claimed |
| EP-4446001-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-10-16 | — | — | EP | claimed |
| WO-2024156688-A1 | BIODEGRADABLE PERFUME COMPOSITION | GIVAUDAN SA (CH) | 2024-08-02 | — | — | WO | claimed |
| EP-4407019-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2024-07-31 | — | — | EP | claimed |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-05-30 | — | — | US | claimed |
| WO-2024046952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOVOZYMES A/S (DK) | 2024-03-07 | — | — | WO | claimed |
| US-20170073614-A1 | Perfume Compositions | GIVAUDAN SA (CH) | 2017-03-16 | — | — | US | claimed |
| EP-2652102-B1 | MOC COMPOSITIONS | GIVAUDAN SA (CH) | 2016-09-14 | — | — | EP | claimed |
| US-9125828-B2 | MOC compositions | GIVAUDAN SA (CH) | 2015-09-08 | — | — | US | claimed |
| EP-1853542-B1 | PROCESS FOR THE PREPARATION OF CIS-2-ACETYL-1,2,3,4,5,6,7,8-OCTAHYDRO-1,2,8,8-TETRAMETHYLNAPHTHALENE | GIVAUDAN SA (CH) | 2015-07-15 | — | — | EP | claimed |
| EP-2382187-B1 | COMPOUND | GIVAUDAN SA (CH) | 2014-03-19 | — | — | EP | claimed |
| US-20130336911-A1 | MOC Compositions | GIVAUDAN SA (CH) | 2013-12-19 | — | — | US | claimed |
| EP-2652102-A1 | MOC COMPOSITIONS | Givaudan SA (CH) | 2013-10-23 | — | — | EP | claimed |
| WO-2012080235-A1 | MOC COMPOSITIONS | GIVAUDAN SA (CH) | 2012-06-21 | — | — | WO | claimed |
| US-7569732-B2 | Cyclisation process | GIVAUDAN SA (CH) | 2009-08-04 | — | — | US | claimed |
| US-20080114189-A1 | Cyclisation Process | GIVAUDAN SA (CH) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114189-A1 | Cyclisation Process | GGPS1, ECH1, ALG8 | ALDH1A1 285/4885TDP1 2960/4885POLB 418/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | ALDH1A1 205/4885TDP1 3363/4885POLB 3087/4885 |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | FABP2, FABP5, FAAH2 | ALDH1A1 413/4885TDP1 4566/4885POLB 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.